GlassScriptPhysician profile
Emily Friedman
NPI 1023500238
$3,174.65
in general payments reported to CMS, 2019-2025
33 companies · $961 in 2025
The $961 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.69 · 2022: $722 · 2023: $718 · 2024: $717 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $792.81 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $595.04 | 2022-2025 | |
| Abbvie INC. | $492.83 | 2021-2025 | |
| Shield Therapeutics INC | $163.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.34 | 2021-2024 | Trintellix |
| Inspire Medical Systems, INC. | $95.44 | 2024-2025 | Inspire |
| Neos Therapeutics, LP | $88.91 | 2022-2025 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $81.66 | 2024-2025 | |
| Corium, LLC | $74.44 | 2023-2024 | Azstarys |
| Mayne Pharma Commercial LLC | $60.55 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $53.64 | 2023-2024 | Quviviq |
| Lundbeck LLC | $49.88 | 2022-2024 | Rexulti |
| Incyte Corporation | $49.78 | 2022-2024 | Opzelura |
| Vertos Medical, INC. | $48.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.69 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2025 | Ofev |
| Grifols USA, LLC | $28.04 | 2024 | Xembify |
| Viiv Healthcare Company | $27.07 | 2025 | Apretude |
| Exact Sciences Corporation | $22.07 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $21.38 | 2025 | Ibsrela |
| Axsome Therapeutics, INC. | $19.96 | 2023 | Auvelity |
| Exeltis, USA INC. | $18.83 | 2025 | Slynd |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.00 | 2021 | |
| Phadia US INC. | $17.62 | 2022 | |
| Linus Health, INC. | $16.58 | 2024 | Core Cognitive Evaluation |
| Hologic Sales and Service, LLC | $16.47 | 2025 | Aptima |
| Pfizer INC. | $16.46 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.25 | 2025 | Airsupra |
| Qiagen, LLC | $16.18 | 2024 | |
| Supernus Pharmaceuticals, INC. | $15.62 | 2023 | Qelbree |
| Acarix USA INC. | $15.27 | 2023 | Cadscor System |
| Lilly USA, LLC | $14.71 | 2022 | |
| Depuy Synthes Sales INC. | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.